p53 Gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines

Gynecologic Oncology

Volumn 60, Issue 1, 1996, Pages 72-80

  Skilling, Jeffrey S ^a   Squatrito, Robert C ^a   Connor, Joseph P ^a   Niemann, Theodore ^a   Buller, Richard E ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; GENE PRODUCT; PROTEIN P53;

ALLELE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENE THERAPY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0030044172     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0014     Document Type: Article

References (46)

1. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction, Cell 70, 523-526 (1992).
2. Levine, A. J., Perry, M. E., Chang, A., Silver, A., Dittmer, D., Wu, M., and Welsh, D. The 1993 Walter Hubert Lecture: The role of the p53 tumor suppressor gene in tumorigenesis, Br. J. Cancer 69, 409-416 (1994).
3. Kohler, M. F., Marks, J. R., Wiseman, R. W., Jacobs, I. J., Davidoff, A. M., Clarke-Pearson, D. L., Soper, J. T., Bast, R. C., and Berchuck, A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer, J. Natl. Cancer Inst. 85(18), 1513-1519 (1991).
4. Kupryjanczyk, J., Thor, A. D., Beauchamp, R., Merritt, V., Edgerton, S. M., Bell, D. A., and Yandell, D. W. p53 gene mutations and protein accumulation in human ovarian cancer, Proc. Natl. Acad. Sci. USA 90, 4961-4965 (1991).
5. Okamoto, A., Sameshima, Y., Yokoyama, S., Terashima, Y., Sugimura, T., Terrada, M., and Yokota, J. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer, Cancer Res. 51, 5171-5176 (1991).
6. Mazars, R., Pujol, P., Maudelonde, T., Jeanteur, P., and Theillet, C. p53 mutations in ovarian cancer: A late event? Oncogene 6, 1685-1690 (1991).
7. Kihana, T., Tsuda, H., Teshima, S., Okada, S., Matsuura, S., and Hirohashi, S. High incidence of P53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy, Jpn. J. Cancer Res. 83, 978-984 (1992).
8. Mok, C. H., Tsao, S. W., Knapp, R. C., Fishbaugh, P. M., and Lau, C. C. Unifocal origin of advanced human epithelial ovarian cancers, Cancer Res. 52, 5119-5122 (1992).
9. Milner, B. J., Allan, L. A., Eccles, D. M., Kitchener, C., Leonard, R. C. F., Kelly, K. F., Parkin, D. E., and Haites, N. E. p53 mutation is a common genetic event in ovarian carcinoma, Cancer Res. 53, 2128-2132 (1993).
10. Naito, M., Satake, M., Sakai, E., Hirano, Y., Tsuchida, N., Kanzaki, H., Ito, Y., and Takahide, M. Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis, Jpn. J. Cancer Res. 83, 1030-1036 (1992).
11. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis, Cancer Res. 654, 4855-4878 (1994).
12. Bayever, E., Iversen, P. L., Bishop, M. R., Sharp, J. G., Tewary, H. K., Arneson, M. A., Pirruccello, S. J., Ruddon, R. W., Kessinger, A., Zon, G., and Armitage, J. O. Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: Initial results of a phase I trial, Antisense Res. Dev. 3, 383-390 (1993).
13. Bayever, E., Haines, K. M., Iversen, P. L., Ruddon, R. W., Pirruccello, S. J., Mountjoy, C. P., Arneson, M. A., and Smith, L. J. Selective cytotoxicity to human leukemic myoblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences, Leuk. Lymphoma 12(3-4), 223-231 (1994).
14. Runnebaum, I. B., Tong, X. W., Moebus, V., Heilmann, V., Kieback, D. G., and Kreienberg, R. Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines, Hum. Genet. 93, 620-624 (1994).
15. Yaginuma, Y., and Westphal, H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines, Cancer Res. 52, 4196-4199 (1992).
16. Hamilton, T. C., Young, R. C., McKoy, W. M., Grotzinger, K. R., Green, J. A., Chu, E. W., Whang-Peng, J., Rogan, A. M., Green, W. R., and Ozols, R. F. Characterization of a human ovarian carcinoma cell line (NIH: OVCAR-3) with androgen and estrogen receptors, Cancer Res. 43, 5379-5389 (1983).
17. Buick, R. N., Pullano, R., and Trent, J. M. Comparative properties of five human ovarian adenocarcinoma cell lines, Cancer Res. 45, 3668-3676 (1985).
18. Behrens, B. C., Hamilton, T. C., Masuda, H., Grotzinger, K. R., Whang-Peng, J., Louie, K. G., Knutsen, T., McKoy, W. M., Young, R. C., and Ozols, R. F. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47, 414-418 (1987).
19. Mazzoni, A., Trave, F., Russo, P., Nicolin, A., and Rustum, Y. M. Generation and characterization of a low-degree drug-resistant human tumor cell line, Oncology 47, 488-494 (1990).
20. Bonavida, B., Tsuchitani, T., Zighelboim, J., and Berek, J. S. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells, Gynecol. Oncol. 38, 333-339 (1990).
21. Freedman, R. S., Pihl, E., Kusyk, C., Gallager, H. S., and Rutledge, F. Characterization of an ovarian carcinoma cell line, Cancer 42, 2352-2359 (1978).
22. Buller, R. E., Niemann, T., Connor, J. P., Squatrito, R. C., Skilling, J., and Anderson, B. Isolation and preliminary characterization of an ovarian carcinoma cell line from a patient with familial ovarian cancer, Gynecol. Oncol. 56, 39-44 (1995).
23. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 9.16-9.19 and Appendix E.6 (1989).
24. Johnson, P., Gray, D., Mowat, M., and Benchimol, S. Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells, Mol. Cell. Biol. 11, 1-11 (1991).
25. Buller, R. E., Anderson, B., Connor, J. P., and Robinson, R. Familial ovarian cancer, Gynecol. Oncol. 51, 160-166 (1993).
26. Toguchida, J., Yamaguchi, T., Ritchie, B., Beauchamp, R. L., Dayton, S. H., Herrera, G. E., Yamamuro, T., Kotoura, Y., Sasaki, M. S., Little, J. B., Weichselbaum, R. R., Ishizaki, K., and Yandell, D. W. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas, Cancer Res. 52, 6194-6199 (1992).
27. Marks, J. R., Davidoff, A. M., Kerns, B. J., Humphrey, P. A., Pence, J. C., Dodge, R. K., Clarke-Pearson, D. L., Iglehart, J. D., Bast, R. C., Jr., and Berchuck, A. Overexpression and mutation of p53 in epithelial ovarian cancer, Cancer Res. 51, 2979-2984 (1991).
28. Lehman, T. A., Bennett, W. P., Metcalf, R. A., Welsch, J. A., Ecker, J., Modali, R. V., Ullrich, S., Romano, J. W., Appella, E., Testa, J. R., Gerwin, B. I., and Harris, C. C. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines, Cancer Res. 51, 4090-4096 (1991).
29. Orita, M., Suzuki, Y., Sekiya, T., and Hayashi, K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction, Genomics 5, 874-879 (1989).
30. Futreal, P. A., Barrett, J. C., and Wiseman, R. W. An Alu polymorphism intragenic to the TP53 gene, Nucleic Acids Res. 19, 6977 (1991).
31. Lazar, V., Hazard, F., Bertin, F., Janin, N., Bellet, D., and Bressac, B. Simple sequence repeat polymorphism within the p53 gene, Oncogene 8(6), 1703-1705 (1993).
32. Olschwang, S., Laurent-Puig, P., Vassal, A., Salmon, R-J., and Thomas, G. Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population, Hum. Genet. 86, 369-370 (1991).
33. 3H]thymidine incorporation assay, J. Immunol. Methods 170(2), 211-224 (1994).
34. Squatrito, R. C., Connor, J. P., and Buller, R. E. Comparison of a novel redox dye cell growth assay to the ATP bioluminescence assay, Gynecol. Oncol. 58, 101-105.
35. Park, D. J., Nakamura, H., Chumakov, A. M., Said, J. W., Miller, C. W., Chen, D. L., and Koeffler, H. P. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines, Oncogene 9, 1899-1906 (1994).
36. King, B. L., Lichtenstein, A., Berenson, J., and Kacinski, B. M. A polymerase chain reaction-based microsatellite typing assay used for tumor cell line identification, Am. J. Pathol. 144, 486-491 (1994).
37. Jego, N., Thomas, G., and Hamelin, R. Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers, Oncogene 8(1), 209-213 (1993).
38. Huang, Y., Yin, J., and Meltzer, S. J. A unique p53 intragenic deletion flanked by short direct repeats results in loss of mRNA expression in a human esophageal carcinoma, Carcinogenesis 15(8), 1653-1655 (1994).
39. Chin, K-V., Ueda, K., Pastan, I., and Gottesman, M. M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53, Science 255, 459-462 (1992).
40. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers, Science 253, 49-53 (1991).
41. Pietenpol, J. A., and Vogelstein, B. No room at the p53 inn, Nature 365, 17-18 (1993).
42. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas, Nature 358, 80-83 (1992).
43. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation, Cell 69, 1237-1245 (1992).
44. Halazonetis, T. D., Davis, L. J., and Kandil, A. N. Wild-type p53 adopts a "mutant"-like conformation when bound to DNA, EMBO J. 12(3), 1021-1028 (1993).
45. Louis, D. N., Von Deimling, A., Chung, R. Y., Rubio, M. P., Whaley, J. M., Eibl, R. H., Ohgaki, H., Wiestler, O. D., Thor, A. D., and Seizinger, B. R. Comparative study of p53 gene and protein alterations in human astrocytic tumors, J. Neuropathol. Exp. Neurol. 52, 31-38 (1993).
46. Zhang, W., Hu, G., Estey, E., Hester, J., and Deisseroth, A. Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells, Oncogene 7, 1645-1647 (1992).